Cerebrolysin

Cerebrolysin is prepared from porcine brain tissue through controlled enzymatic proteolysis, yielding a heterogeneous mixture of low-molecular-weight peptide fragments (below 10,000 daltons) and free amino acids. This size profile allows the fragments to traverse the blood-brain barrier, where they are proposed to exert neurotrophic-like effects within the central nervous system.

The peptide mixture contains constituents that mimic, or may directly represent, endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). These fragments are proposed to bind neuronal tyrosine kinase receptors (principally TrkB and TrkA), activating downstream pro-survival pathways including PI3K/Akt and MAPK/ERK, which suppress mitochondria-mediated apoptosis and support synaptic plasticity.

Preclinical studies report that Cerebrolysin upregulates endogenous BDNF, VEGF, and IGF-1 expression while downregulating the pro-inflammatory cytokine TNF-alpha, suggesting a pleiotropic anti-inflammatory and pro-regenerative profile. Synaptic protein synthesis and neuroplasticity markers are also enhanced in animal models.

The precise identities and relative contributions of individual peptide constituents remain incompletely characterized. Batch variability in composition is an acknowledged limitation for both preclinical reproducibility and clinical interpretation of results.

The most extensively studied indication is mild-to-moderate Alzheimer's disease (AD). A 2002 multicenter, randomized, double-blind, placebo-controlled trial by Panisset et al. (n=192; PMID 12111446) administering 30 mL IV five days per week for four weeks found a significant advantage on the Clinician's Interview-Based Impression of Change (CIBIC+) at week 12, with 76% of treated versus 57% of placebo patients rated as responders (p=0.007). A 2011 RCT by Alvarez et al. (n=133; PMID 20500802) testing 10, 30, and 60 mL doses over 12 weeks reported significant improvements in global clinical function across all three dosages at 24 weeks. A 2015 meta-analysis by Gauthier et al. pooling six RCTs (DOI 10.1159/000377672) found a statistically significant cognitive benefit at four weeks (SMD -0.40; 95% CI -0.66 to -0.13; p=0.003) and improved global clinical ratings (OR 3.32; 95% CI 1.20-9.21; p=0.02), though the cognitive effect was not sustained at six months (p=0.17).

For traumatic brain injury (TBI), a 2023 systematic review and meta-analysis by Jarosz et al. (Brain Sciences; ten studies, n=8,749; DOI 10.3390/brainsci13030507) found significant improvements in Glasgow Coma Scale scores (difference in means 1.344; p=0.028) and Glasgow Outcome Scale scores (DM 0.422; p<0.001), with no significant effect on mortality or length of hospital stay.

For acute ischemic stroke, the 2023 Cochrane review by Ziganshina et al. (seven RCTs, n=1,773; DOI 10.1002/14651858.CD007026.pub7) found little to no difference in all-cause death (RR 0.96) and showed that Cerebrolysin more than doubled non-fatal serious adverse events relative to placebo (RR 2.39), with the excess most pronounced at higher doses. The Cochrane reviewers concluded that reliable evidence does not support routine use. Most of the positive AD and TBI trials have been funded or co-sponsored by the manufacturer; independently conducted analyses, particularly the Cochrane stroke review, show weaker or unfavorable results.

Typical dosage: 5-10 ml (multiple times weekly).

Cerebrolysin is not approved in the United States and carries no FDA prescribing label. The following is derived from published clinical trial protocols and manufacturer-issued treatment guidance for jurisdictions where the drug is registered, including Austria, Russia, China, and parts of Southeast Asia.

Cerebrolysin is a sterile aqueous solution administered by injection only; it is not available in oral form. Volumes of 10 mL or less may be given as a slow direct intravenous push over approximately three minutes. Volumes exceeding 10 mL are diluted in 100 to 250 mL of 0.9% sodium chloride solution and infused over 15 to 60 minutes. Intramuscular injection at lower volumes (2 to 5 mL) has been reported in community settings.

Indication-specific protocols observed in published trials: • Alzheimer's disease: 10 to 30 mL IV daily for four-week treatment courses, repeated two to four times per year; the Panisset 2002 RCT used 30 mL IV five days per week for four weeks. • Traumatic brain injury: 10 to 50 mL IV daily for 10 to 30 days in acute and subacute phases, per the range observed across trials included in the Jarosz 2023 meta-analysis. • Acute ischemic stroke: 30 mL IV daily for 10 days, as used in trials reviewed by the 2023 Cochrane analysis.

This content is for educational reference only and does not constitute medical advice. Cerebrolysin is an injectable prescription preparation requiring administration by a qualified healthcare provider; it is not appropriate for unsupervised or self-administration.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most clinically documented combination is Cerebrolysin with the acetylcholinesterase inhibitor donepezil in Alzheimer's disease. Research indicates that combined therapy significantly elevates serum BDNF levels, and the combination appears to augment and prolong the neurotrophic response compared to Cerebrolysin alone. However, large-scale RCTs confirming clinical superiority of the combination over donepezil monotherapy are not yet available, and this use remains exploratory.

Citicoline (CDP-choline) has been co-administered with Cerebrolysin in traumatic brain injury. A 2025 retrospective cohort study by Schlager et al. (n=80; PMC12705382) comparing combined citicoline plus Cerebrolysin against citicoline alone found no statistically significant difference in Glasgow Outcome Scale Extended scores at six months (p=0.417), though a non-significant trend favored the combination in the more severely injured patients.

Combination with piracetam, other racetam-class compounds, and memantine for cognitive enhancement is reported in community nootropic forums and online self-experimentation logs. None of these combinations have been evaluated in controlled clinical trials, and they should be considered anecdotal only. The theoretical rationale for combining a neurotrophic agent with an NMDA-receptor antagonist such as memantine exists, but published human data are absent.

Cerebrolysin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally well-tolerated. Possible: dizziness, agitation

Adverse effects reported in clinical trials include headache, dizziness, nausea, sweating, weight loss, anxiety, and agitation. Injection-site reactions occur with both IV and IM routes. In the Panisset 2002 RCT (n=192), 64% of treated patients versus 73% of placebo patients reported at least one adverse event, suggesting that many events may be unrelated to the drug. The Alzheimer's Drug Discovery Foundation notes that adverse effect rates were broadly comparable between Cerebrolysin and placebo groups across the AD trial program.

The most significant safety signal in the published literature comes from the 2023 Cochrane systematic review of stroke trials (seven RCTs, n=1,773), in which Cerebrolysin more than doubled the rate of non-fatal serious adverse events compared to placebo (RR 2.39), with the excess most pronounced at higher doses. Fatal serious adverse events did not differ significantly between groups. The Cochrane reviewers concluded that Cerebrolysin's use in this context is unsafe and that any future research must rigorously assess serious adverse event risk.

Rare but potentially serious reactions include hypersensitivity responses such as urticaria, pruritus, and anaphylaxis, attributable to the porcine protein origin. Seizure activity has been reported; the preparation may increase seizure frequency in susceptible individuals.

Established contraindications: • Known hypersensitivity to porcine-derived products or any constituent of the preparation • Epilepsy or active seizure disorder • Severe renal impairment • Pregnancy and breastfeeding (insufficient safety data)

The porcine origin also raises dietary, religious, and ethical considerations for individuals observing restrictions on products derived from pigs.